-
CSCO Experts’ Voice | Professor Xinan Sheng on China-Tailored RCC Guidelines and Innovative Therapies
01 Oncology Frontier – Urology Frontier: As a standing member and secretary-general of the CSCO RCC Expert Committee, you have helped draft and update multiple guideline editions. Could you share…
-
Professor Juan Li: Evaluation and Management Strategies for Kidney Injury During Targeted Plus Immunotherapy in Advanced Renal Cell Carcinoma
Clinical Manifestations and Incidence of Kidney Injury Oncology Frontier: T+I therapy has become the standard for advanced RCC, but kidney injury remains a critical issue. Based on your clinical experience…
-
Giuseppe Curigliano on the Clinical Impact and Future of T-DXd Combo Therapy | CSCO 2025
The Current Cornerstone: The Historical Status and Limitations of the CLEOPATRA Regimen For over a decade, the first-line standard of care for HER2-positive metastatic breast cancer has been established by…
-
Owen O’Connor Provides an In-depth Analysis of the New Paradigm in T-cell Lymphoma Treatment | CSCO 2025
The 2025 Chinese Society of Clinical Oncology (CSCO) Annual Meeting was grandly held in the golden autumn season, gathering top experts from the global field of oncology. In the lymphoma session, the renowned American scholar, Professor Owen O’Connor, delivered a splendid presentation on the topic “REASONS FOR OPTIMISM IN TREATING THE T-CELL MALIGNANCIES: A BIOLOGICAL…
Connecting Medical Expertise through Media